PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34350063-5	2021	Alternol facilitated tumor-associated antigen uptake and cross-presentation, CD8 + T-cell priming, and T-cell infiltration in tumor-draining lymph nodes (LNs) and tumors.	Alternol	0-8	CD8a molecule	Homo sapiens	77-80
34350063-4	2021	Alternol triggered ICD in prostate cancer cells, as evidenced by the release of damage-associated molecular patterns (DAMPs) (i.e., calreticulin, CALR; high mobility group protein B1, HMGB1; and adenosine triphosphate, ATP) and pro-inflammatory cytokine (i.e., interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-8) expression.	Alternol	0-8	calreticulin	Homo sapiens	132-144
34350063-4	2021	Alternol triggered ICD in prostate cancer cells, as evidenced by the release of damage-associated molecular patterns (DAMPs) (i.e., calreticulin, CALR; high mobility group protein B1, HMGB1; and adenosine triphosphate, ATP) and pro-inflammatory cytokine (i.e., interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-8) expression.	Alternol	0-8	calreticulin	Homo sapiens	146-150
33841136-13	2021	Moreover, alternol increased the level of CHOP, which is necessary for the enhancing effect of alternol on TRAIL-induced apoptosis, given that downregulation of CHOP abrogated the synergistic effect.	Alternol	10-18	DNA damage inducible transcript 3	Homo sapiens	42-46
34350063-4	2021	Alternol triggered ICD in prostate cancer cells, as evidenced by the release of damage-associated molecular patterns (DAMPs) (i.e., calreticulin, CALR; high mobility group protein B1, HMGB1; and adenosine triphosphate, ATP) and pro-inflammatory cytokine (i.e., interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-8) expression.	Alternol	0-8	high mobility group box 1	Homo sapiens	152-182
34350063-4	2021	Alternol triggered ICD in prostate cancer cells, as evidenced by the release of damage-associated molecular patterns (DAMPs) (i.e., calreticulin, CALR; high mobility group protein B1, HMGB1; and adenosine triphosphate, ATP) and pro-inflammatory cytokine (i.e., interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-8) expression.	Alternol	0-8	high mobility group box 1	Homo sapiens	184-189
34350063-4	2021	Alternol triggered ICD in prostate cancer cells, as evidenced by the release of damage-associated molecular patterns (DAMPs) (i.e., calreticulin, CALR; high mobility group protein B1, HMGB1; and adenosine triphosphate, ATP) and pro-inflammatory cytokine (i.e., interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-8) expression.	Alternol	0-8	interleukin 1 alpha	Homo sapiens	286-294
34350063-4	2021	Alternol triggered ICD in prostate cancer cells, as evidenced by the release of damage-associated molecular patterns (DAMPs) (i.e., calreticulin, CALR; high mobility group protein B1, HMGB1; and adenosine triphosphate, ATP) and pro-inflammatory cytokine (i.e., interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-8) expression.	Alternol	0-8	interleukin 6	Homo sapiens	296-300
34350063-4	2021	Alternol triggered ICD in prostate cancer cells, as evidenced by the release of damage-associated molecular patterns (DAMPs) (i.e., calreticulin, CALR; high mobility group protein B1, HMGB1; and adenosine triphosphate, ATP) and pro-inflammatory cytokine (i.e., interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-8) expression.	Alternol	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	306-310
33841136-13	2021	Moreover, alternol increased the level of CHOP, which is necessary for the enhancing effect of alternol on TRAIL-induced apoptosis, given that downregulation of CHOP abrogated the synergistic effect.	Alternol	10-18	TNF superfamily member 10	Homo sapiens	107-112
33841136-13	2021	Moreover, alternol increased the level of CHOP, which is necessary for the enhancing effect of alternol on TRAIL-induced apoptosis, given that downregulation of CHOP abrogated the synergistic effect.	Alternol	95-103	DNA damage inducible transcript 3	Homo sapiens	42-46
33841136-13	2021	Moreover, alternol increased the level of CHOP, which is necessary for the enhancing effect of alternol on TRAIL-induced apoptosis, given that downregulation of CHOP abrogated the synergistic effect.	Alternol	95-103	TNF superfamily member 10	Homo sapiens	107-112
33841136-0	2021	Alternol Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis.	Alternol	0-8	TNF superfamily member 10	Homo sapiens	45-50
33841136-4	2021	In our research, we discovered that alternol can sensitize TRAIL-induced apoptosis in renal carcinoma cells (RCCs).	Alternol	36-44	TNF superfamily member 10	Homo sapiens	59-64
27624867-0	2017	Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.	Alternol	0-8	signal transducer and activator of transcription 3	Homo sapiens	92-97
33841136-10	2021	Results: When the mechanisms were investigated, we discovered that alternol increased DR5 expression.	Alternol	67-75	TNF receptor superfamily member 10b	Homo sapiens	86-89
33841136-11	2021	DR5 knockdown by siRNA eliminated the enhanced effect of alternol on TRAIL-mediated apoptosis.	Alternol	57-65	TNF receptor superfamily member 10b	Homo sapiens	0-3
33841136-11	2021	DR5 knockdown by siRNA eliminated the enhanced effect of alternol on TRAIL-mediated apoptosis.	Alternol	57-65	TNF superfamily member 10	Homo sapiens	69-74
31103463-5	2019	However, XDH/XO inhibition by specific small chemical inhibitors or gene silencing reduced total ROS levels and protected cells from apoptosis induced by Alternol.	Alternol	154-162	xanthine dehydrogenase	Homo sapiens	9-12
31103463-6	2019	Further analysis revealed that Alternol treatment significantly enhanced XDH oxidative activity and induced a strong protein oxidation-related damage in malignant but not benign cells.	Alternol	31-39	xanthine dehydrogenase	Homo sapiens	73-76
31103463-7	2019	Interestingly, benign cells exerted a strong spike in anti-oxidant SOD and catalase activities compared to malignant cells after Alternol treatment.	Alternol	129-137	superoxide dismutase 1	Homo sapiens	67-70
31103463-8	2019	Cell-based protein-ligand engagement and in-silicon docking analysis showed that Alternol interacts with XDH protein on the catalytic domain with two amino acid residues away from its substrate binding sites.	Alternol	81-89	xanthine dehydrogenase	Homo sapiens	105-108
31103463-9	2019	Taken together, our data demonstrate that Alternol treatment enhances XDH oxidative activity, leading to ROS-dependent apoptotic cell death.	Alternol	42-50	xanthine dehydrogenase	Homo sapiens	70-73
33841136-14	2021	DR5 upregulation induced by alternol required the production of reactive oxygen species (ROS).	Alternol	28-36	TNF receptor superfamily member 10b	Homo sapiens	0-3
33841136-16	2021	Conclusion: Taken together, our research suggested that alternol increased TRAIL-mediated apoptosis via inhibiting antiapoptotic proteins and upregulating DR5 levels via ROS generation and the CHOP pathway.	Alternol	56-64	TNF superfamily member 10	Homo sapiens	75-80
33841136-16	2021	Conclusion: Taken together, our research suggested that alternol increased TRAIL-mediated apoptosis via inhibiting antiapoptotic proteins and upregulating DR5 levels via ROS generation and the CHOP pathway.	Alternol	56-64	TNF receptor superfamily member 10b	Homo sapiens	155-158
33841136-16	2021	Conclusion: Taken together, our research suggested that alternol increased TRAIL-mediated apoptosis via inhibiting antiapoptotic proteins and upregulating DR5 levels via ROS generation and the CHOP pathway.	Alternol	56-64	DNA damage inducible transcript 3	Homo sapiens	193-197
32699806-3	2020	In in vitro cell culture experiments Alternol inhibits prostate cancer cell proliferation by causing cell cycle arrest, reduces the expression of Bcl-2 and other pro-survival proteins, increases the level of radical oxygen species by activating xanthine dehydrogenase, blunts mitochondrial aerobic respiration and ATP production, and triggers autophagy flux.	Alternol	37-45	BCL2 apoptosis regulator	Homo sapiens	146-151
32699806-3	2020	In in vitro cell culture experiments Alternol inhibits prostate cancer cell proliferation by causing cell cycle arrest, reduces the expression of Bcl-2 and other pro-survival proteins, increases the level of radical oxygen species by activating xanthine dehydrogenase, blunts mitochondrial aerobic respiration and ATP production, and triggers autophagy flux.	Alternol	37-45	xanthine dehydrogenase	Homo sapiens	245-267
27624867-0	2017	Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.	Alternol	0-8	mitogen-activated protein kinase 3	Homo sapiens	106-110
27624867-6	2017	Moreover, alternol treatment inhibited signal transducer and activator of transcription-3 (STAT3) phosphorylation in 143B and MG63 human OS cells, as evaluated using a STAT3-dependent dual luciferase reporter system.	Alternol	10-18	signal transducer and activator of transcription 3	Homo sapiens	39-89
27624867-6	2017	Moreover, alternol treatment inhibited signal transducer and activator of transcription-3 (STAT3) phosphorylation in 143B and MG63 human OS cells, as evaluated using a STAT3-dependent dual luciferase reporter system.	Alternol	10-18	signal transducer and activator of transcription 3	Homo sapiens	91-96
27624867-6	2017	Moreover, alternol treatment inhibited signal transducer and activator of transcription-3 (STAT3) phosphorylation in 143B and MG63 human OS cells, as evaluated using a STAT3-dependent dual luciferase reporter system.	Alternol	10-18	signal transducer and activator of transcription 3	Homo sapiens	168-173
27624867-7	2017	Exposure to alternol resulted in excessive reactive oxygen species (ROS) generation and Jun amino-terminal kinases (JNK), extracellular signal-regulated kinases (ERK1/2) and p38 activation.	Alternol	12-20	mitogen-activated protein kinase 8	Homo sapiens	116-119
27624867-7	2017	Exposure to alternol resulted in excessive reactive oxygen species (ROS) generation and Jun amino-terminal kinases (JNK), extracellular signal-regulated kinases (ERK1/2) and p38 activation.	Alternol	12-20	mitogen-activated protein kinase 3	Homo sapiens	162-168
27624867-7	2017	Exposure to alternol resulted in excessive reactive oxygen species (ROS) generation and Jun amino-terminal kinases (JNK), extracellular signal-regulated kinases (ERK1/2) and p38 activation.	Alternol	12-20	mitogen-activated protein kinase 1	Homo sapiens	174-177
27624867-8	2017	Furthermore, alternol-induced cell death was significantly restored in the presence of the ROS scavenger, N-acetyl-l-cysteine (NAC) or a caspase inhibitor Z-VAD-FMK.	Alternol	13-21	X-linked Kx blood group	Homo sapiens	127-130
27624867-11	2017	Immunohistochemistry revealed that alternol treatment resulted in down-regulation of phosph-STAT3 Tyr705 and up-regulation of cleaved caspase-3 and phosph-SAPK (Stress-activated protein kinases)/JNK expression.	Alternol	35-43	signal transducer and activator of transcription 3	Homo sapiens	92-97
27624867-11	2017	Immunohistochemistry revealed that alternol treatment resulted in down-regulation of phosph-STAT3 Tyr705 and up-regulation of cleaved caspase-3 and phosph-SAPK (Stress-activated protein kinases)/JNK expression.	Alternol	35-43	mitogen-activated protein kinase 9	Homo sapiens	155-159
27624867-11	2017	Immunohistochemistry revealed that alternol treatment resulted in down-regulation of phosph-STAT3 Tyr705 and up-regulation of cleaved caspase-3 and phosph-SAPK (Stress-activated protein kinases)/JNK expression.	Alternol	35-43	mitogen-activated protein kinase 8	Homo sapiens	195-198
27624867-12	2017	Taken together, our results reveal that alternol suppresses cell proliferation, migration and induces apoptosis, cell cycle arrest by modulating of ROS-dependent MAPK and STAT3 signalling pathways in human OS cells.	Alternol	40-48	mitogen-activated protein kinase 3	Homo sapiens	162-166
27624867-12	2017	Taken together, our results reveal that alternol suppresses cell proliferation, migration and induces apoptosis, cell cycle arrest by modulating of ROS-dependent MAPK and STAT3 signalling pathways in human OS cells.	Alternol	40-48	signal transducer and activator of transcription 3	Homo sapiens	171-176
24688053-4	2014	Further analyses revealed that Alternol-induced cell death was an apoptotic response in a dose- and time-dependent manner, as evidenced by the appearance of apoptosis hallmarks such as caspase-3 processing and PARP cleavage.	Alternol	31-39	caspase 3	Homo sapiens	185-194
25914461-8	2015	Alternol activated caspase 3, upregulated p53 and p21 expression, and downregulated Bcl-2 expression in a dose-dependent manner.	Alternol	0-8	caspase 3	Homo sapiens	19-28
25914461-8	2015	Alternol activated caspase 3, upregulated p53 and p21 expression, and downregulated Bcl-2 expression in a dose-dependent manner.	Alternol	0-8	tumor protein p53	Homo sapiens	42-45
25914461-8	2015	Alternol activated caspase 3, upregulated p53 and p21 expression, and downregulated Bcl-2 expression in a dose-dependent manner.	Alternol	0-8	H3 histone pseudogene 16	Homo sapiens	50-53
25914461-8	2015	Alternol activated caspase 3, upregulated p53 and p21 expression, and downregulated Bcl-2 expression in a dose-dependent manner.	Alternol	0-8	BCL2 apoptosis regulator	Homo sapiens	84-89
27278753-5	2016	NaOH alkaline lysis and oxidation of Dopa indicated that alternol enhanced the melanin content and tyrosinase activity of the B16F0 cells and results also showed a dose-response relationship.	Alternol	57-65	tyrosinase	Mus musculus	99-109
27278753-7	2016	Furthermore, the mRNA levels of tyrosinase, Trp1 and Trp2 were increased by alternol.	Alternol	76-84	tyrosinase	Mus musculus	32-42
27278753-7	2016	Furthermore, the mRNA levels of tyrosinase, Trp1 and Trp2 were increased by alternol.	Alternol	76-84	tyrosinase-related protein 1	Mus musculus	44-48
27278753-7	2016	Furthermore, the mRNA levels of tyrosinase, Trp1 and Trp2 were increased by alternol.	Alternol	76-84	tRNA proline 2	Mus musculus	53-57
24688053-4	2014	Further analyses revealed that Alternol-induced cell death was an apoptotic response in a dose- and time-dependent manner, as evidenced by the appearance of apoptosis hallmarks such as caspase-3 processing and PARP cleavage.	Alternol	31-39	poly(ADP-ribose) polymerase 1	Homo sapiens	210-214
24688053-6	2014	We also demonstrated that the proapoptotic Bax protein was activated after Alternol treatment and was critical for Alternol-induced apoptosis.	Alternol	75-83	BCL2 associated X, apoptosis regulator	Homo sapiens	43-46
24688053-6	2014	We also demonstrated that the proapoptotic Bax protein was activated after Alternol treatment and was critical for Alternol-induced apoptosis.	Alternol	115-123	BCL2 associated X, apoptosis regulator	Homo sapiens	43-46
24078466-7	2014	The inhibition of HCC invasion by alternol was associated with the suppression of MMP-9 expression and reversal of epithelial-to-mesenchymal transition (EMT).	Alternol	34-42	matrix metallopeptidase 9	Homo sapiens	82-87
17713842-5	2007	When the cells were treated with Alternol, chromatin condensation and phosphatidylserine externalization were observed with the down-regulation of the pro-survival gene Bcl-2 and the activation of caspase-3, caspase-9, but not caspase-8.	Alternol	33-41	B cell leukemia/lymphoma 2	Mus musculus	169-174
17713842-5	2007	When the cells were treated with Alternol, chromatin condensation and phosphatidylserine externalization were observed with the down-regulation of the pro-survival gene Bcl-2 and the activation of caspase-3, caspase-9, but not caspase-8.	Alternol	33-41	caspase 3	Mus musculus	197-206
17713842-5	2007	When the cells were treated with Alternol, chromatin condensation and phosphatidylserine externalization were observed with the down-regulation of the pro-survival gene Bcl-2 and the activation of caspase-3, caspase-9, but not caspase-8.	Alternol	33-41	caspase 9	Mus musculus	208-217
17713842-5	2007	When the cells were treated with Alternol, chromatin condensation and phosphatidylserine externalization were observed with the down-regulation of the pro-survival gene Bcl-2 and the activation of caspase-3, caspase-9, but not caspase-8.	Alternol	33-41	caspase 8	Mus musculus	227-236
24352978-8	2014	The mechanism by which alternol inhibits B16F0 proliferation in vitro may be associated with the inhibition of CDK2 and PCNA, and the activation of p21.	Alternol	23-31	cyclin-dependent kinase 2	Mus musculus	111-115
24352978-8	2014	The mechanism by which alternol inhibits B16F0 proliferation in vitro may be associated with the inhibition of CDK2 and PCNA, and the activation of p21.	Alternol	23-31	proliferating cell nuclear antigen	Mus musculus	120-124
24352978-8	2014	The mechanism by which alternol inhibits B16F0 proliferation in vitro may be associated with the inhibition of CDK2 and PCNA, and the activation of p21.	Alternol	23-31	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	148-151